REACH Côte d'Ivoire: Feasibility and acceptability of integrating mass distribution of azithromycin to children 1-11 Months into a trachoma mass drug administration campaign to reduce child mortality

In-Depth Interview Guide for CDD Supervisors

Number	Item	Response options	Code
1.	Participant ID number	complete with the locality ID number and the interview sequence number)	**[SUPV--___ --_ ___ ___]**
2.	Date of interview	DD/MM/YY	
3.	Location of interview		
4.	Interviewer ID number		
5.	Setting	Rural Urban	1 2
6.	Health Facility/facilities supervisor is associated with		
7.	Language of interview		

8.	Transcriber ID number		
9.	Date of transcription	DD/MM/YY	

READ:
We are going to start the interview now. I will use an audio recorder to more accurately capture what you have to say. Are you ready?

[*TURN ON RECORDER NOW*]

Interview start time **[___ ___ : ___ ___]**

To begin, I would like to ask you some questions about your thoughts on MDA.

1. What kind of training did you receive before the MDA?
    a. Could you describe your training?
    b. Did you feel like you were trained in everything you needed prior to the MDA? If not, what else would you have liked the training to include?
    c. What aspects of the training do you think should be strengthened?
    d. What topics were not included that you think are needed?

2. Over the past few years, we have learned that azithromycin given twice a year to children ages 1 to 11 months through community drug distribution campaigns can reduce mortality for children. The Ministry of Health has decided to pilot test this approach, which is why the CDDs in your community were asked to give azithromycin to children from 1 to 5 months in addition to children and adults 6 months and older during the trachoma campaign instead of tetracycline ointment. How do you feel about giving children ages 1-11 months azithromycin to improve survival?
    a. Do you feel comfortable with this? Why or why not?
    b. Do you have any concerns about this? If so, what are they?

3. Next I'd like to ask you some questions about the community sensitization efforts that took place prior to and during the campaign. Were you aware of the sensitization efforts that were done before the MDA including TV or radio messages, posters and town criers?
    a. Did you hear any of the messages that promoted azithromycin to reduce child mortality?
    b. Did you feel that the message about azithromycin improving child survival was well understood by parents and caregivers? Why or why not?
    c. Are there ways that messages or sensitization could be improved? (Probe for suggestions related to: message content, message delivery including the frequency or messages or where messages were delivered, etc.)

4. Were you involved in any of the sensitization activities (such as meeting with village heads)?
    a. If yes, what did you think about these activities?
    b. Are there ways that these activities could be improved?

5. What do you think about the implementation of the MDA?
    a. Did you experience any challenges during the MDA? Please describe them. How did you resolve the challenges?
    b. What do you think is needed for the MDA to run more smoothly/be better?

6. Can you tell me about the experiences of the CDDs who you supervise during the MDA?
    a. Did you or any of the CDDs you supervise notice any issues with the process of weighing the 1 to 5 months old to calculate dosage?
    b. What about with the process of calculating dosage of the medication for children 1-11 months?
    c. How did CDDs dispose of single use syringes used to administer the medication to children 1 to 5 months?

7. Were the any problems with communication between CDDs and supervisors? Please describe problems.

8. Did you talk to any caregivers who refused azithromycin for their children? If yes,:
    a. What were the caregivers' concerns?
    b. What did you tell the caregivers?
    c. Were you able to overcome these concerns and give azithromycin to the child?

9. What did you think about the MDA data collection forms used for children under the age of 1?
    a. Did you notice any problems with the completed data collection forms you collected from the CDDs?

b. At the end of the MDA, were there any problems summarizing the data for the MDA campaign and reporting to the district? What were the problems? What could be done to improve this?

10. To improve child survival, mass distribution of azithromycin to children 1 to 11 months must happen every 6 months. However, MDA for trachoma only happens once per year.
    a. What are your thoughts about carrying out a second MDA targeting only 1 – 11-month-old children?
    b. What changes need to be made for this to happen successfully?
    c. What concerns, if any, do you have about doing a second MDA within a year that targets children 1 to 11 months only?

Before we end our interview, do you have any final thoughts or suggestions for us?
Thank you for your time. We appreciate the answers you have given us.

Interview end time **[___ ___ : ___ ___]**

GO TO THE NEXT PAGE.

Interview Notes	
The overall demeanor of the participants – for example, describe if the participants were sad, uninterested, forthcoming, timid, relaxed, defensive, etc.	
Any interruptions that occurred during the IDI	
Cultural factors mentioned that would be important for others outside the local context to understand	
Questions that were difficult for the participants to understand and suggest modifications	
Issues and/or participant questions that need to be followed-up.	
Any information that contradicts with what you have learned in other interviews.	
Themes or patterns that are emerging [e.g. information that you are hearing over and over again from IDI participants].	
Additional general notes	